Walking meditation trial aims to strengthen resilience in neurodegenerative disease patients

NCT ID NCT07285954

First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 23 times

Summary

This study tests a walking meditation program called iWalk for adults with neurodegenerative diseases like multiple sclerosis. The goal is to see if it's feasible and helps improve resilience, stress regulation, and thinking skills. Researchers will enroll 90 participants and measure outcomes like resilience scales and cognitive tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University of Illinois Urbana-Champaign

    RECRUITING

    Urbana, Illinois, 61801, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

walking meditation program (iWalk)

What this could lead to

If it works, this could offer a simple, drug-free way to help people with neurodegenerative diseases feel more resilient and manage stress better.

What could go wrong

This is a small, early feasibility study with only 90 participants, so results may not apply widely. The intervention is behavioral, so benefits may be modest or hard to measure.

Conditions

The condition(s) this trial relates to.

Emotional Regulation neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.